These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 34244306)

  • 1. Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.
    Wolfson B; Padget MR; Schlom J; Hodge JW
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
    Devulapally R; Sekar TV; Paulmurugan R
    Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    Obrero M; Yu DV; Shapiro DJ
    J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
    Lin HY; Han HW; Wang YS; He DL; Sun WX; Feng L; Wen ZL; Yang MK; Lu GH; Wang XM; Qi JL; Yang YH
    Chin Med; 2020; 15():23. PubMed ID: 32175001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12.
    Pearce ST; Liu H; Jordan VC
    J Biol Chem; 2003 Feb; 278(9):7630-8. PubMed ID: 12496244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.
    O'Leary KA; Bates AM; Jin WJ; Burkel BM; Sriramaneni RN; Emma SE; Nystuen EJ; Sumiec EG; Ponik SM; Morris ZS; Schuler LA
    Breast Cancer Res; 2023 Jun; 25(1):68. PubMed ID: 37312163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
    Chen Y; Li Z; He Y; Shang D; Pan J; Wang H; Chen H; Zhu Z; Wan L; Wang X
    Toxicol Appl Pharmacol; 2014 Mar; 275(2):176-81. PubMed ID: 24440569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
    Girgert R; Emons G; Gründker C
    Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
    Li Y; Birnbaumer L; Teng CT
    Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.
    Block M; Fister S; Emons G; Seeber S; Gründker C; Günthert AR
    Anticancer Res; 2010 Jun; 30(6):2025-31. PubMed ID: 20651347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
    Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
    Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
    Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
    Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments.
    Ao A; Morrison BJ; Wang H; López JA; Reynolds BA; Lu J
    PLoS One; 2011 Apr; 6(4):e18810. PubMed ID: 21533195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.